Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recognising and managing depression is an important part of post-stroke treatment, but some treatments should be used with caution until more is known about the risks, according to new evidence published in the Cochrane Library today.

Close up horizontal image of female practitioner holding hand of older man

The George Institute for Global Health researchers analysed the results of 49 trials involving over 3,000 people with depression following a stroke and found that while psychological therapy or medication could be useful, the latter may come with some potentially harmful side effects. 

Senior author Professor Maree Hackett, Program Head, Mental Health at The George Institute said that while depression is an important consequence of stroke that impacts on recovery, it is often not detected or is inadequately treated. 

“Management of people who have experienced a stroke tends to focus on the physical effects of the stroke and the psychological effects may be overlooked. Having depression after stroke can hamper recovery by reducing a person’s motivation or making them unable to keep up with the recommended rehabilitation,” she said. 

Read the full story on the University of Oxford website

Similar stories

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.